As access to Sayana® Press (subcutaneous depot medroxyprogesterone acetate, or DMPA-SC in Uniject™) expands globally, PATH has monitored product consumption in four pilot introduction countries: Burkina Faso, Niger, Senegal, and Uganda. As the introduction phase draws to a close and all four countries move toward scale-up, they are transitioning Sayana Press consumption data collection into national information systems.

Highlights of monitoring data for the full pilot period (July 2014–June 2016) include:

More than 490,300 doses of Sayana Press were administered in Burkina Faso, Niger, Senegal, and Uganda.
PATH estimates that Sayana Press was administered to more than 120,000 women using modern family planning for the first time.
Niger administered the highest proportion of Sayana Press to new users, with just less than half of all doses going to first-time users of modern contraception. Sayana Press reaches a largely rural population in Niger, and the pilot represented the first time injectables were made available at the most peripheral level of the health system.
Niger and Uganda administered the highest proportions of Sayana Press to women younger than 25 years—almost half of the total number of doses administered in each country.
More information is available in this summary of PATH’s monitoring work and results. If you are interested in reading the full monitoring report, please email sayanapress@path.org. Full monitoring results from all four countries will be posted online in 2017.

*The small sample in Senegal is due to the sentinel site system established to gather data for certain indicators.